About me
1997 Research Assistant: Department of Medical Biochemistry, Flinders University
1998-1999 Research Assistant at the Department of Cytogenetics, Women’s and Children’s Hospital. South Australia
2004-2011 Postdoctoral Researcher: Cell Growth and Differentiation Laboratory, Department of Human Immunology, Centre for Cancer Biology, Adelaide.
2012- Head, Cancer Cell Signalling Unit, Molecular Signalling Laboratory, Department of Human Immunology, Centre for Cancer Biology, Adelaide. Laboratory Head: Professor Stuart Pitson
2017- Associate faculty member of the Center of Cancer Biology
2011-2021 Affiliate Senior Lecturer, Discipline of Medicine, Faculty of Health Sciences, University of Adelaide
2016-2019 Adjunct Senior research fellow, School of Pharmacy and Medical Sciences, University of South Australia
2018- Member of the executive committee, South Australian Cancer Biobank (SACRB) 2019- Member of the Australian patient derived xenograph consortium
Research
Excludes commercial-in-confidence projects.
Bioengineering a Superior Humanized Haematopoietic Niche Derived from Mesenchymal Stem Cells for Pre-Clinical Avatar Cancer Trials, MRFF-Stem Cell Therapies Mission, 01/08/2023 - 31/01/2026
Examining the pathogenic bone marrow microenvironment, HSC stress, and targeting clonal evolution to prevent development of leukaemia in predisposed individuals, Leukaemia Foundation - Grant in Aid (National Research Program), 10/07/2023 - 09/05/2025
Stereotactic alignment and injection system for the generation of xenografts of human brain tumours into the brains of mice for pre-clinical testing of new and existing therapeutics, Neurosurgical Research Foundation, 01/01/2018 - 31/12/2018
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2025 |
Open access
|
| 2024 |
Open access
1
|
| 2024 |
Open access
1
1
1
|
| 2024 |
Open access
27
24
1
|
| 2023 |
Open access
50
48
279
|
| 2023 |
Open access
30
30
12
|
| 2022 |
Open access
18
18
8
|
| 2022 |
Open access
16
16
3
|
| 2022 |
Open access
37
32
73
|
| 2022 |
Open access
12
14
1
|
| 2022 |
Open access
15
13
89
|
| 2019 |
Open access
25
22
5
|
| 2019 |
Open access
14
14
|
| 2019 |
Open access
13
13
1
|
| 2018 |
Open access
62
65
1
|
| 2017 |
Open access
71
71
56
|
| 2017 |
Open access
29
27
|
| 2016 |
Open access
54
50
|
| 2015 |
Open access
65
64
|
| 2014 |
Open access
71
65
|
| 2013 |
Open access
16
15
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Australian National University | AUSTRALIA |
| Flinders University | AUSTRALIA |
| Harvard University | UNITED STATES |
| Monash University | AUSTRALIA |
| QIMR Berghofer Medical Research Institute | AUSTRALIA |
| SA Pathology | AUSTRALIA |
| St. Vincent's Institute of Medical Research | AUSTRALIA |
| Stanford University | UNITED STATES |
| University of Adelaide | AUSTRALIA |
| University of New South Wales | AUSTRALIA |
| University of North Carolina at Chapel Hill | UNITED STATES |
| University of South Australia | AUSTRALIA |
| University of Sydney | AUSTRALIA |
| University of Technology Sydney | AUSTRALIA |
| University of Texas | UNITED STATES |
| Victor Chang Cardiac Research Institute | AUSTRALIA |
| Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
| Westmead Hospital | AUSTRALIA |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| 110188-Enhancing therapy of acute myeloid leukaemia by predicting drivers of relapse | Current |
| Targeting sphingosine kinase 1 in acute myeloid leukaemia | Completed |
| Targeting sphingosine kinase 1 to overcome venetoclax resistance in acute myeloid leukemia | Completed |
